Plasmocure™ - Mycoplasma Elimination Reagent
Alternative Mycoplasma Removal Agent
In very rare cases, mycoplasmas resistant to Plasmocin™ have been reported. To eradicate these mycoplasmas, InvivoGen has developed a new antimycoplasma agent called Plasmocure™.
Plasmocure™ combines two antibiotics that act through different mechanisms of action than those in Plasmocin™. A two-week treatment with Plasmocure™ was found sufficient to completely eliminate the mycoplasmas. A moderate toxicity can be observed during the course of the treatment but full recovery of the cell line is expected once mycoplasmas are eliminated.
Product concentration: 100 mg/ml
Elimination of mycoplasmas in two weeks (recommended concentration of 50 μg/ml)
Shipped at room temperature
Plasmocure™ is provided as a cell culture tested, sterile filtered solution at a concentration of 100 mg/ml.
Plasmocure™ contains two bactericidal components belonging to different antibiotic families. They both act by inhibiting the protein synthesis but use distinct mechanisms. The first antibiotic binds to the 50S subunit of the ribosome and blocks the peptidyltransferase activity. The second antibiotic binds to the isoleucyl-tRNA synthetase and halts the incorporation of isoleucine into bacterial proteins. These two specific and separate targets are found only in mycoplasmas and Gram positive bacteria, and are completely absent in eukaryotic cells. The cytotoxicity of Plasmocure™ is low, however a slowdown of cell growth may be observed at high concentrations due to the inhibition of mitochondria respiration. At the end of the treatment, when Plasmocure™ is removed from the culture medium, the cells return rapidly to their normal growth rate.
Recent articles using InvivoGen Plasmocure™ - Mycoplasma Elimination Reagent
- 2016 - PLoS One., 11(3):e0150460.
Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
Lee H, Kang S, Kim W.
- 2016 - Cell Death Dis., 7(8):e2322.
TLR and NLRP3 inflammasome-dependent innate immune responses to tumor-derived autophagosomes (DRibbles).
Xing Y. et al.
- 2015 - Arch Pathol Lab Med., 139(11):1349-61.
MicroRNA-375 suppresses extracellular matrix degradation and invadopodial activity in head and neck squamous cell carcinoma.
Jimenez L, Sharma VP, Condeelis J, Harris T, Ow TJ, Prystowsky MB, Childs G, Segall JE.
- 2012 - Immunity, 36(3):464-476
An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages.
Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C